Floatz logo

FENTANYL

Colon Adenocarcinoma

University of Kansas Medical CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Colon Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Cetuximab
Merck Sharp & Dohme LLC
Phase 3BB
Nivolumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

FENTANYL is also rated in:

Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →
PainDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →